Although the role of dopamine (DA) in malignant tumors has been reported, its function in premalignant lesions is unknown. Herein we report that the stimulation of DA D 2 receptors in endothelial cells in ultraviolet B (UVB)-induced cutaneous lesions in mice significantly reduced the tumor number, tumor burden, and malignant squamous cell carcinoma in these animals. DA D 2 receptor agonist inhibited VEGFA-dependent proangiogenic genes in vitro and in vivo. However, the mice pretreated with selective DA D 2 receptor antagonist inhibited the actions of the agonist, thereby suggesting that the action of DA was through its D 2 receptors in the endothelial cells. To our knowledge, this study is the first to report DAmediated regulation of pathogenesis and progression of UVB-induced premalignant skin lesions.Prevention Relevance: This investigation demonstrates the role of dopamine and its D 2 receptors in UVB induced premalignant squamous cell skin lesions and how DA through its D 2 receptors inhibits the development and progression of these lesions and subsequently prevents squamous cell carcinoma of the skin.This study is aimed to identify the role of DA as a regulator of UVB-induced skin tumorigenesis and investigate whether it plays a role in regulating VEGF-induced angiogenesis in the pathogenesis and progression of premalignant cutaneous squamous cell lesions.
Materials and Methods
Cells and reagentsPrimary human dermal microvascular endothelial cells (HMVEC-D; catalog no. CC-2543, Lonza) were cultured in microvascular endothelial cell growth medium-2 (catalog no. CC-3202, Lonza). These primary endothelial cells were authenticated through short tandem repeat profiling, and Mycoplasma was assessed via PCR. For in vitro experiments, HMVEC-D cells were deprived of serum and growth factors for 12 hours and were then either treated with selective DA D 2 receptor agonist quinpirole (catalog no. Q102, Sigma) or pretreated with selective DA D 2 receptor antagonist eticlopride (catalog no. E101, Sigma) followed by quinpirole treatment. Recombinant human VEGF was purchased from R&D Systems (catalog no. 293-VE, R&D Systems, MN, USA) and used as a positive control to stimulate the VEGF pathway in the HMVEC-D cells. Sarcoma 180 (S180) cells were from ATCC, and human umbilical vein endothelial cells were from ATCC.